(Q63815760)

English

Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

short name

GRID (English)

0 references

title

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib (English)

0 references

0 references

0 references

0 references

0 references

0 references